BioTech
REGN

Regeneron Pharmaceuticals: IPR&D Charge To Negatively Impact Q3 EPS By Approx. $0.43

October 07, 2024 — 08:30 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Regeneron Pharmaceuticals (REGN) said it currently expects that financial results for the third quarter 2024 will include an acquired in-process research and development charge of approximately $56 million on a pre-tax basis. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the third quarter by approximately $0.43. Regeneron's results for the third quarter have not been finalized.

The company noted that the IPR&D charge relates to development milestone and up-front payments in connection with collaboration and licensing agreements.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

BioTech
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

REGN

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.